This summer has brought good news for the New Deal project! Two new scientific papers have been published by some of the New Deal partners.
Molecular Structure and Function of Janus Kinases: Implications for the Development of Inhibitors. Garrido-Trigo A. and Salas A. 2020. Journal of Crohn’s and Colitis, 14 (2): S713-S724.
Inflammatory bowel disease (IBD) is characterized by a chronic inflammation of the gastrointestinal tract. This is triggered by molecules called cytokines through signalling pathways that involve proteins like JAKs. The role of these molecules in inflammation makes them a potential target for IBD treatments, thus understanding them is vital to exploit JAKs pharmacologically. Our partners from IDIBAPS have published a detailed review about these interesting proteins!
Modulating the Crosstalk between the Tumor and Its Microenvironment Using RNA Interference: A Treatment Strategy for Hepatocellular Carcinoma. Mroweh et al. 2020. Int. J. Mol. Sci. 21(15): 5250.
In the New Deal project, we target these JAK proteins and inhibit them using RNA interference. This process hinders the JAK production within the cells, thus reducing inflammation. This innovative strategy can be applied as a treatment for several diseases. One of them is hepatocellular carcinoma, and our partners from Inserm have published a review about how RNA interference could help to treat this kind of tumours.